Abcuro is an immuno-therapeutic company aiming to help treat cancer and autoimmune diseases. Using pre-clinical antibody development, Abcuro develops clinical treatments that target lektin receptors on cytotoxic T cells. Other advancements being made in the company include the ABC015 anti-KLRG1 blocking antibody. Abcuro was founded by Stefano Gullà in 2015 and is headquartered in Boston, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/17/2023 | Series B-1 | $33.13MM | $xx.xx | $307.61MM | Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital | |
Price per Share
$xx.xx
Shares Outstanding
7,542,862
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital
|
||||||
08/17/2023 | Series B | $121.87MM | $xx.xx | $307.61MM | Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital | |
Price per Share
$xx.xx
Shares Outstanding
22,200,405
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital
|
||||||
01/07/2021 | Series A-1 | $42MM | $xx.xx | $77.96MM | Sanofi Ventures, Mass General Brigham Ventures, Pontifax, Hongsen Investment Group, RA Capital Management, Samsara BioCapital | |
Price per Share
$xx.xx
Shares Outstanding
7,650,686
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Sanofi Ventures, Mass General Brigham Ventures, Pontifax, Hongsen Investment Group, RA Capital Management, Samsara BioCapital
|
||||||
11/09/2018 | Series A | $8MM | $xx.xx | $18.86MM | ShangPharma Innovation, Partners Innovation Fund, Kaitai Capital | |
Price per Share
$xx.xx
Shares Outstanding
1,619,201
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
ShangPharma Innovation, Partners Innovation Fund, Kaitai Capital
|
||||||
11/30/2016 | Series Seed | $2.25MM | $xx.xx | $5.62MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
671,141
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3.0
Key Investors
Undisclosed Investors
|